PL426879A1 - Combination of isothiocyanates with organic selen compounds in drug carriers as a new pharmaceutical with antitumor activity - Google Patents

Combination of isothiocyanates with organic selen compounds in drug carriers as a new pharmaceutical with antitumor activity

Info

Publication number
PL426879A1
PL426879A1 PL426879A PL42687918A PL426879A1 PL 426879 A1 PL426879 A1 PL 426879A1 PL 426879 A PL426879 A PL 426879A PL 42687918 A PL42687918 A PL 42687918A PL 426879 A1 PL426879 A1 PL 426879A1
Authority
PL
Poland
Prior art keywords
selen
isothiocyanates
compounds
organic
combination
Prior art date
Application number
PL426879A
Other languages
Polish (pl)
Other versions
PL238526B1 (en
Inventor
Katarzyna WIKTORSKA
Lidia Mielczarek
Pamela Krug
Maciej Mazur
Zdzisław CHILMONCZYK
Piotr Suchocki
Marta Bartel
Barbara Wysocka
Original Assignee
Narodowy Instytut Leków
Uniwersytet Warszawski
Warszawski Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Narodowy Instytut Leków, Uniwersytet Warszawski, Warszawski Uniwersytet Medyczny filed Critical Narodowy Instytut Leków
Priority to PL426879A priority Critical patent/PL238526B1/en
Priority to PCT/PL2019/050050 priority patent/WO2020050731A1/en
Priority to EP19857747.0A priority patent/EP3846790A4/en
Publication of PL426879A1 publication Critical patent/PL426879A1/en
Publication of PL238526B1 publication Critical patent/PL238526B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Przedmiotem zgłoszenia jest formulacja farmaceutyczna o właściwościach przeciwnowotworowych zawierająca co najmniej jeden izotiocyjanian oraz selol jako substancję wzmacniającą działanie izotiocyjanianu do zastosowania w leczeniu nowotworu, przy czym co najmniej jeden izotiocyjanian oraz selol umieszczone są w nośniku lipidowym.The subject of the application is a pharmaceutical formulation with antitumor properties containing at least one isothiocyanate and selol as an isothiocyanate enhancer for use in the treatment of cancer, wherein at least one isothiocyanate and selol are contained in a lipid carrier.

PL426879A 2018-09-04 2018-09-04 Combination of isothiocyanates with organic selen compounds in drug carriers as a new pharmaceutical with antitumor activity PL238526B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL426879A PL238526B1 (en) 2018-09-04 2018-09-04 Combination of isothiocyanates with organic selen compounds in drug carriers as a new pharmaceutical with antitumor activity
PCT/PL2019/050050 WO2020050731A1 (en) 2018-09-04 2019-09-03 Combination of isothiocyanates with organic selenium compounds encapsulated in drug carriers as new pharmaceutical agents with anti-tumor activity
EP19857747.0A EP3846790A4 (en) 2018-09-04 2019-09-03 Combination of isothiocyanates with organic selenium compounds encapsulated in drug carriers as new pharmaceutical agents with anti-tumor activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL426879A PL238526B1 (en) 2018-09-04 2018-09-04 Combination of isothiocyanates with organic selen compounds in drug carriers as a new pharmaceutical with antitumor activity

Publications (2)

Publication Number Publication Date
PL426879A1 true PL426879A1 (en) 2020-03-09
PL238526B1 PL238526B1 (en) 2021-08-30

Family

ID=69709583

Family Applications (1)

Application Number Title Priority Date Filing Date
PL426879A PL238526B1 (en) 2018-09-04 2018-09-04 Combination of isothiocyanates with organic selen compounds in drug carriers as a new pharmaceutical with antitumor activity

Country Status (3)

Country Link
EP (1) EP3846790A4 (en)
PL (1) PL238526B1 (en)
WO (1) WO2020050731A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL241189B1 (en) * 2018-09-27 2022-08-22 Narodowy Inst Lekow Pharmaceutical formulation containing selenitetrigliceride and cytostatic for use in cancer treatment
JPWO2021193835A1 (en) * 2020-03-25 2021-09-30
CN115944617A (en) * 2022-12-07 2023-04-11 浙江大学医学院附属儿童医院 Application of natural phenethylisothiocyanate in cruciferous vegetables in preparation of anti-endometrial cancer drug

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL176530B1 (en) * 1994-06-29 1999-06-30 Bohdan Fitak Anticarcinogenous preparation and method of obtaining same
PL233619B1 (en) * 2013-01-30 2019-11-29 Piotr Roman Suchocki Preventive and therapeutic formulation and a method for its manufacture
PL229503B1 (en) * 2015-09-21 2018-07-31 Narodowy Inst Lekow Pharmaceutical formulation containing isocyanates and dexorubicin to be applied in treatment of tumours

Also Published As

Publication number Publication date
PL238526B1 (en) 2021-08-30
WO2020050731A1 (en) 2020-03-12
EP3846790A1 (en) 2021-07-14
EP3846790A4 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
CL2019001551A1 (en) 7-phenylethylamino-4h-pyrimido [4,5-d] [1,3] -oxazin-2-one compounds as mutant idh1 and idh2 inhibitors
CO2019008487A2 (en) Quinazoline Compound
CL2019001874A1 (en) Context-permissive isoform-specific tgfß1 inhibitors and their use.
ECSP18094983A (en) PIRAZOLE DERIVATIVES AS INHIBITORS OF PLASMA CALICREIN
BR112017000550A2 (en) antiproliferative compounds and methods of use thereof
PL426879A1 (en) Combination of isothiocyanates with organic selen compounds in drug carriers as a new pharmaceutical with antitumor activity
BR112015019064A8 (en) use of a composition comprising nanoparticles comprising paclitaxel and an albumin for the treatment of melanoma and kit
BR112016000489A8 (en) compound, pharmaceutical composition comprising it, use of the composition and methods for making compounds
BR112015016681A8 (en) use of nanoparticles comprising paclitaxel and an albumin, kit, drug, composition and unit dosage form for the treatment of pancreatic cancer
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
CL2012003415A1 (en) Compounds derived from 2-oxo-piperidine and 1,1-dioxide-thiazine, mdm2 inhibitors; pharmaceutical composition that includes them; and its use for the treatment of cancer.
CO2023001165A2 (en) Tricyclic urea compounds as jak2 v617f inhibitors
BR112018068412A2 (en) compound, pharmaceutical composition, method of treating myelodysplastic syndrome and method for killing a tumor cell
UY37832A (en) DIHYDROOXADIAZINONES
CL2019002427A1 (en) Inhibition of smarca2 for the treatment of cancer.
AR113270A1 (en) HETEROARYL COMPOUND WITH NITROGEN CONTENT AND ITS PHARMACEUTICAL USE
CO2022008817A2 (en) Macrocycles for use in the treatment of diseases
BR112018014723A2 (en) bacterial ghosts for cancer treatment
MX2020004513A (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same.
CL2019003288A1 (en) A pharmaceutical combination for the treatment of cancer.
CL2022003206A1 (en) Quinolone-derived compounds and their use for the treatment of cancer (div. sol. 202102501)
PL427216A1 (en) Pharmaceutical formulation containing selenitetrigliceride and cytostatic for use in cancer treatment
MX2019006749A (en) Cellular senescence activating compounds.
EA201992852A1 (en) DOSAGE DIAGRAM FOR TESETAXEL AND CAPETSITABINE
PL414021A1 (en) Pharmaceutical formulation containing isocyanates and dexorubicin to be applied in treatment of tumours